MedTrace Logo

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

NCT03291002 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2021-11-04

No results posted yet for this study

Summary

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

Conditions

  • Melanoma (Skin)
  • Squamous Cell Carcinoma of the Skin
  • Carcinoma, Squamous Cell of Head and Neck
  • Carcinoma, Adenoid Cystic

Interventions

BIOLOGICAL

CV8102

CV8102 alone

BIOLOGICAL

CV8102 + anti-PD-1 therapy

CV8102 in combination with standard of care anti-PD-1 therapy

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Cromos Pharma LLC

    collaborator INDUSTRY

  • CureVac

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-25
Primary Completion
2022-10-31
Completion
2023-02-28

Countries

  • Austria
  • France
  • Germany
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03291002 on ClinicalTrials.gov